Drug duo takes on rare cancers: new hope for HER2 patients

NCT ID NCT06136897

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This phase II trial is testing whether a combination of two targeted drugs, trastuzumab and pertuzumab, can shrink tumors in patients with HER2-amplified cancers that are not breast, stomach, or colorectal. The drugs block signals that make cancer cells grow and help the immune system attack them. About 35 adults with advanced solid tumors will receive the treatment, and researchers will measure how many patients respond and how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab and pertuzumab (antibody drugs that target HER2 protein on cancer cells)
What this could lead to: If successful, this could offer a new treatment option for patients with rare HER2-amplified cancers that are not breast, stomach, or colorectal.
What could go wrong: This is a small, early-phase trial (35 participants) with no control group. The drugs may not work for all cancer types, and side effects like heart problems or infusion reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED REFRACTORY SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT SOLID NEOPLASM

Contacts and locations

Locations

ECOG-ACRIN Cancer Research Group

Philadelphia, Pennsylvania, 19103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.